CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for VIDAC PHARMA HOLDING PLC is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

VIDAC PHARMA HOLDING PLC
20-22 Wenlock Road
LONDON, N1 7GU  United Kingdom Ticker: T9GT9G
Business Summary
Vidac Pharma Holding PLC is a clinical-stage biopharmaceutical company. It is focused on discovering and developing medicines to help people suffering from a range of oncologic and onco-dermatologic diseases. It develops anti-cancer drugs by modifying the hyper glycolytic tumor microenvironment, targeting the overexpression and wrong anchoring of the Hexokinase 2 metabolic checkpoint (HK2) in cancer cells, to renormalize the tumor microenvironment and selectively provoke their programmed death without affecting surrounding normal tissue. Its pipeline includes VDA-1102 Ointment, VDA-1102 IV and VDA-1275. VDA-1102 ointment is a drug that selectively targets malignant cutaneous cells with minimal effects on surrounding healthy skin. VDA-1102 IV is an anti-neoplastic agent that utilizes a mechanism of action involving selective modulation of VDAC/HK2. VDA-1275 is a potent small molecule new chemical entity (NCE) with a mechanism of action that selectively modulates VDAC/HK2 interaction.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
6/30/202312/31/2022Yes----

Industries
SIC Code Description
2834 Pharmaceutical preparations
8731 Commercial physical and biological research
6719 Offices of holding companies, not elsewhere classified

General Information
Number of Employees: 4 (As of 12/31/2021)
Outstanding Shares: 53,420,948 (As of 6/30/2023)
Stock Exchange: BWB


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Sunday, April 28, 2024